Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of Hexaxim Co-administered with MenC Vaccine in Infants
NCT01839175Phase 3Completed
- Sponsor
- Sanofi
- Start
- Apr 2013
- Primary completion
- Jul 2014
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of hexaxim in diphtheria, Tetanus, pertussis, hepatitis B (HBV), poliomyelitis, sponsored by Sanofi. Started Apr 2013; status: completed.
02
Drugs
hexaxim
03
Conditions
diphtheriaTetanuspertussishepatitis B (HBV)poliomyelitis
Beyond the preview
Go deeper on NCT01839175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01839175.